TITLE: Vortioxetine for Adults with Post-traumatic Stress Disorder: Clinical Effectiveness and Guidelines

DATE: 27 June 2016

RESEARCH QUESTIONS

1. What is the clinical effectiveness of vortioxetine for the treatment of adults with post-traumatic stress disorder?

2. What are the evidence-based guidelines for the use of vortioxetine for the treatment of adults with post-traumatic stress disorder?

KEY FINDINGS

No relevant literature was identified regarding the clinical effectiveness of vortioxetine for the treatment of adults with post-traumatic stress disorder. In addition, no relevant literature was identified regarding the use of vortioxetine for the treatment of adults with post-traumatic stress disorder.

METHODS

A limited literature search was conducted on key resources including PubMed, The Cochrane Library, University of York Centre for Reviews and Dissemination (CRD) databases, Canadian and major international health technology agencies, as well as a focused Internet search. No filters were applied to limit the retrieval by study type. Where possible, retrieval was limited to the human population. The search was also limited to English language documents published between January 1, 2011 and June 21, 2016. Internet links were provided, where available.

SELECTION CRITERIA

One reviewer screened citations and selected studies based on the inclusion criteria presented in Table 1.

Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources of the best evidence on the topic that the Canadian Agency for Drugs and Technologies in Health (CADTH) could identify using all reasonable efforts within the time allowed. Rapid responses should be considered along with other types of information and health care considerations. The information included in this response is not intended to replace professional medical advice, nor should it be construed as a recommendation for or against the use of a particular health technology. Readers are also cautioned that a lack of good quality evidence does not necessarily mean a lack of effectiveness particularly in the case of new and emerging health technologies, for which little information can be found, but which may in future prove to be effective. While CADTH has taken care in the preparation of the report to ensure that its contents are accurate, complete and up to date, CADTH does not make any guarantee to that effect. CADTH is not liable for any loss or damages resulting from use of the information in the report.

Copyright: This report contains CADTH copyright material and may contain material in which a third party owns copyright. This report may be used for the purposes of research or private study only. It may not be copied, posted on a web site, redistributed by email or stored on an electronic system without the prior written permission of CADTH or applicable copyright owner.

Links: This report may contain links to other information available on the websites of third parties on the Internet. CADTH does not have control over the content of such sites. Use of third party sites is governed by the owners’ own terms and conditions.
### Table 1: Selection Criteria

<table>
<thead>
<tr>
<th>Selection Criteria</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Population</strong></td>
<td>Adults (≥ 18 years old) with post-traumatic stress disorder (PTSD)</td>
</tr>
<tr>
<td><strong>Intervention</strong></td>
<td>Vortioxetine</td>
</tr>
<tr>
<td><strong>Comparator</strong></td>
<td>Q1: Any active treatment; Usual care; Placebo; No treatment</td>
</tr>
<tr>
<td></td>
<td>Q2: No comparator</td>
</tr>
<tr>
<td><strong>Outcomes</strong></td>
<td>Q1: PTSD symptom reduction, safety and harms;</td>
</tr>
<tr>
<td></td>
<td>Q2: Guidelines</td>
</tr>
<tr>
<td><strong>Study Designs</strong></td>
<td>Health technology assessments, systematic reviews, meta-analyses, randomized controlled trials, non-randomized studies, evidence-based guidelines</td>
</tr>
</tbody>
</table>

### RESULTS

No relevant health technology assessments, systematic reviews, meta-analyses, randomized controlled trials or non-randomized studies were identified regarding the clinical effectiveness of vortioxetine for the treatment of adults with post-traumatic stress disorder. In addition, no relevant evidence-based guidelines were identified regarding the use of vortioxetine for the treatment of adults with post-traumatic stress disorder.

References of potential interest are provided in the appendix.

### Health Technology Assessments

No literature identified.

### Systematic Reviews and Meta-analyses

No literature identified.

### Randomized Controlled Trials

No literature identified.

### Non-Randomized Studies

No literature identified.

### Guidelines and Recommendations

No literature identified.

### PREPARED BY:

Canadian Agency for Drugs and Technologies in Health  
Tel: 1-866-898-8439  
[www.cadth.ca](http://www.cadth.ca)
APPENDIX – FURTHER INFORMATION:

Previous CADTH Reports

Vortioxetine Not Specified


A summary of key findings of CADTH reports assessing the available evidence on pharmacological, psychological and alternative options for the treatment of PTSD.


A table that summarizes and compares available clinical practice guidelines from Canadian and international guideline groups for the prevention and treatment of PTSD.

Randomized Controlled Trial – Planned


Review Articles


Additional References

Product Monograph


See: Potential Off-label Uses, page 2
See: Tables B.4, page 142;
Table B.5, page 146